Can You Get PRP Injections on the NHS?

PRP injections are not routinely available on the NHS. The National Institute for Health and Care Excellence (NICE), which guides what treatments the health service funds, has declined to recommend PRP for its most commonly requested use, knee osteoarthritis, citing uncertainty in the evidence. That position, first stated in 2014, has not meaningfully changed, and it effectively locks PRP out of standard NHS provision for musculoskeletal conditions. Most people who want PRP in the UK pay out of pocket at private clinics, where a single session typically costs several hundred pounds. The picture is more nuanced than a flat “no,” though, and understanding why the NHS takes this stance reveals a lot about where PRP actually works, where it probably doesn’t, and what your alternatives are.

Why NICE Has Not Approved PRP

NICE evaluates treatments based on clinical evidence and cost-effectiveness before recommending them for NHS use. For knee osteoarthritis, which is the condition most commonly treated with PRP worldwide, NICE concluded that the evidence was too uncertain to justify a recommendation. A systematic review of international clinical practice guidelines found that out of eleven guidelines addressing PRP for knee osteoarthritis, nine were either uncertain or unable to make a formal recommendation, and two recommended against it. NICE fell into the “do not recommend” camp specifically because of that evidence gap.¹

This doesn’t mean NICE believes PRP is dangerous or categorically useless. It means the body of evidence, as NICE reads it, isn’t strong or consistent enough to warrant spending public money on it when established alternatives exist. For a treatment to enter NHS formularies, it generally needs robust randomized trials showing clear patient benefit over existing options, plus a reasonable cost profile. PRP hasn’t cleared that bar for any musculoskeletal condition in the UK.

The Evidence That Shapes the NHS Position

The evidence base for PRP is sprawling and frustratingly mixed. Some trials show benefits; others show none. The problem isn’t that research is lacking in volume but that results vary wildly depending on the condition being treated, the way the PRP is prepared, and what it’s being compared against.

For Achilles tendon ruptures, one of the best-designed UK trials, the PATH-2 study, randomized patients to receive either a PRP injection or a placebo injection alongside standard non-surgical care. At 24 weeks, there was no meaningful difference in muscle-tendon function between the two groups. At two years, outcomes remained virtually identical, with average patient-reported scores of about 82 in the PRP group and 84 in the placebo group.² The earlier time points told the same story: no evidence of benefit for pain, function, or any secondary measure at four, seven, thirteen, or twenty-four weeks.³

For tennis elbow, another condition frequently marketed as a PRP success story, a Cochrane review pooling data from eight placebo-controlled trials found that pain improvements on a ten-point scale and functional improvements on a hundred-point scale both sat firmly around the null effect. The review’s authors concluded there was insufficient evidence to support the ongoing use of PRP injections for tennis elbow.⁴

These are not obscure conditions chosen to make PRP look bad. Achilles injuries and tennis elbow are two of the most commonly cited indications in the sports-medicine PRP market. When the best-designed trials for those conditions show no benefit over placebo, it’s easy to see why a conservative body like NICE declines to recommend the treatment.

Where PRP Shows More Promise

Not all PRP research is negative. In chronic wound healing, particularly diabetic foot ulcers, some studies report encouraging results. One study of PRP injections into the wound bed over four weeks found that about 40% of chronic ulcers healed completely and the remaining 60% showed healing progress after eight weeks.⁵ Animal studies have also shown that PRP promotes re-epithelialization, increases local blood vessel density, and enhances the release of growth factors that drive tissue repair.⁶

The biological rationale is genuinely interesting. PRP concentrates a person’s own platelets, which, when activated, release growth factors that stimulate blood vessel formation, cell proliferation, and collagen production. Those are all things wounds and injured tissue need.⁷ The science behind how PRP could work is solid. The question is whether concentrating those growth factors and injecting them into a specific site reliably produces a clinical benefit the patient can feel, in a way that beats cheaper alternatives. For orthopaedic conditions, the answer so far has been inconsistent.

This split between promising wound-healing data and disappointing musculoskeletal results matters for NHS decision-making. The NHS might eventually fund PRP for tissue viability purposes, perhaps in specialist wound clinics for hard-to-heal diabetic ulcers, before it ever funds PRP for sore knees. But even in wound care, larger confirmatory trials are needed before that happens.

The Preparation Problem

One reason PRP trials produce such variable results is that “PRP” is not a single standardized product. The concentration of platelets, the presence or absence of white blood cells (leukocytes), the activation method, and the number of spins in the centrifuge all differ between clinics and between studies. This matters clinically. An umbrella review comparing leukocyte-rich and leukocyte-poor PRP for rotator cuff surgery found that leukocyte-poor preparations reduced retear rates and pain, while leukocyte-rich preparations did not show the same benefits on most outcome measures.⁸

This means that two patients could each receive “PRP” at two different clinics and get meaningfully different products. Until there is a standardized preparation protocol, comparing results across trials is like comparing different drugs under the same brand name. It’s one of the major reasons regulatory bodies remain cautious: they cannot approve something when nobody has pinned down exactly what “it” is. For you as a potential patient, it also means that the marketing claim “PRP injections” tells you almost nothing about what you’d actually receive.

The Placebo Effect Complicates Everything

A subtlety that private clinics rarely discuss is that injection procedures tend to carry a strong placebo effect, especially for pain conditions. In a randomized trial of PRP versus saline injections for hip osteoarthritis, the saline control group showed significant improvements in physical function and general health scores at one and six months after the injection. The researchers attributed this to placebo effects, noting that the reasons for these improvements remain unclear.⁹

This is a real challenge for evaluating PRP. Many patients who pay privately for PRP injections and feel better afterward are experiencing something genuine: they feel less pain and function better. But without a proper comparison to a placebo injection, there’s no way to know whether the platelets did the work or the injection ritual did. The consultation, the scan, the sense that a medical professional is doing something active to the joint, even the needle itself can all produce meaningful pain relief. This doesn’t make the improvement fake, but it does make it difficult to attribute to the PRP specifically. For the NHS, spending public money on a treatment whose benefits may be explained by placebo dynamics is a hard sell.

What the NHS Offers Instead

If you’re dealing with knee osteoarthritis or a tendon injury in the UK, the NHS has its own pathway. For knee osteoarthritis, NICE recommends a combination of structured exercise, weight management if relevant, and pain relief. Corticosteroid injections are available as an adjunct for moderate to severe pain, though their relief tends to be short-lived: one trial found that corticosteroid injections reduced pain significantly at one month but that the benefit had faded by three months.¹⁰

Structured exercise programmes hold up well in comparison. A trial comparing an eight-week supervised exercise programme to PRP treatment for knee osteoarthritis found that the exercise group showed significantly better scores on pain, symptoms, and daily activities at the end of the programme.¹¹ Exercise is free, carries no injection risks, and benefits cardiovascular health, mood, and general function on top of joint symptoms. It’s less glamorous than an injection, but the evidence behind it is considerably stronger. For severe cases that don’t respond to conservative management, total knee replacement remains the established surgical option on the NHS and has decades of outcomes data behind it.

Going Private for PRP

If you decide to pursue PRP privately, you should know what you’re getting into. Most UK clinics charge between £300 and £500 per injection session, and many protocols involve a course of two or three sessions spaced a few weeks apart. That puts total treatment costs in the range of £600 to £1,500. A cost-effectiveness analysis using US healthcare costs found that PRP for knee osteoarthritis did not offer better value than proceeding straight to knee replacement from a healthcare payer perspective, because replacement produced slightly more quality-adjusted life years at a slightly lower total cost.¹² A separate analysis of nine randomized trials found that PRP could be cost-effective relative to hyaluronic acid and saline if the total treatment cost stayed below roughly $1,200 over twelve months.¹³

The cost-effectiveness picture, in other words, is marginal even in optimistic analyses. For someone with mild to moderate knee osteoarthritis who isn’t ready for or doesn’t want surgery, paying privately for PRP is a reasonable personal choice, provided you go in with realistic expectations. The evidence suggests any improvement is likely to be modest and may not exceed what a thorough exercise programme could achieve. If a clinic promises dramatic results, be skeptical.

Private clinics in the UK are not required to follow NICE guidelines, so they’re free to offer PRP. However, PRP is classified as a medical procedure, not a pharmaceutical, so it doesn’t go through the drug-approval process. There is no standardized regulation of the preparation kits, centrifuge settings, or injection protocols that private clinics use. You’re largely trusting the individual practitioner’s training and judgment.

Safety Considerations

Because PRP is derived from your own blood, the risk of allergic reaction or immune rejection is extremely low. That said, the procedure is not risk-free. A literature survey of adverse events found that the most commonly reported problem was postoperative infection, likely arising from contamination during blood collection, centrifugation, or injection rather than from the PRP itself. Other reported adverse events included inflammation, nodule development at the injection site, and, in rare cases involving facial injections, blindness.¹⁴ Because PRP cannot be sterilized the way a manufactured drug can, maintaining a sterile preparation environment is critical. If you’re considering a private clinic, ask about their preparation protocol and infection-control measures.

The PATH-2 trial provides some reassurance on general safety in a musculoskeletal context. Complication rates related to the injection were similar between the PRP and placebo groups, with roughly three-quarters of participants in both groups reporting at least one adverse event related to either the Achilles rupture itself or the injection.³ In other words, PRP didn’t appear to cause extra harm compared to a sham injection, which is consistent with its overall reputation as a low-risk procedure even when its benefits are questionable.

Could Individual Funding Requests Work?

The NHS has a mechanism called an Individual Funding Request (IFR) for situations where a patient’s clinical circumstances are exceptional enough to justify funding a treatment not normally offered. In theory, a patient and their consultant could submit an IFR arguing that PRP is clinically necessary for their specific case. In practice, IFRs for PRP are rarely successful. The bar for exceptionality is high, typically requiring evidence that the patient’s condition is clinically distinct from other patients with the same diagnosis, not just that their symptoms are severe. A GP or consultant who believes PRP might help you can submit the request, but manage your expectations: most Clinical Commissioning Groups and Integrated Care Boards interpret the evidence on PRP the same way NICE does.

How PRP’s Future on the NHS Might Change

The NHS position isn’t permanent. If large, well-designed, UK-based randomized trials demonstrate clear benefit for a specific condition using a standardized PRP formulation, NICE could revise its guidance. The key obstacles right now are the preparation variability problem and the absence of large confirmatory trials that use sham injections as controls. Trials that compare PRP to no treatment, or to exercise alone, can’t rule out placebo effects and carry less weight in NICE’s assessments.

There is also growing interest in whether specific PRP formulations might work for specific conditions, rather than treating “PRP” as a single intervention applied everywhere. If researchers can identify that, say, a leukocyte-poor preparation at a defined platelet concentration produces reliable benefit for a defined stage of knee osteoarthritis, that tightly specified product-condition pairing could be evaluated and potentially approved. The evidence on leukocyte-poor PRP for rotator cuff retear rates, for instance, is more encouraging than the evidence for PRP injections into osteoarthritic joints.⁸ Whether that kind of granular evidence emerges quickly enough to shift NHS policy is another question entirely. For now, if you want PRP in the UK, the private route remains effectively the only option.